GLP-1 receptor agonists effective for weight loss in obesity without diabetes

FHS
May 29, 2024
8:59 am

The benefit-harm balance of initiating Glucagon-like Peptide-1 (GLP-1) receptor agonists (RAs) versus a placebo intervention.

Opinion | How Much Do Physicians Really Know About FDA Drug and Device Regulation?

Dhruva, Kesselheim, and Redberg are all professors of medicine. Medications, from blood pressure control to chemotherapy, and medical devices, from hip replacements to heart valves,

January 29, 2024

Anthos stroke drug appears safer than common blood thinner in mid-stage trial

PHILADELPHIA — An investigational drug aimed at preventing strokes significantly reduced the risk of bleeding compared with a commonly used blood thinner for stroke prevention,

November 12, 2023

Molecular Devices opens custom-built site in Cardiff for manufacturing of patient-derived organoids

Today, Molecular Devices, LLC., a leading high-performance life science solutions provider, officially opened its custom-built site in Cardiff, UK.

June 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.